2006
DOI: 10.1001/archderm.142.12.1654
|View full text |Cite
|
Sign up to set email alerts
|

Development of Alopecia Areata Universalis in a Patient Receiving Adalimumab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
11
0

Year Published

2008
2008
2018
2018

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 64 publications
(11 citation statements)
references
References 4 publications
0
11
0
Order By: Relevance
“…Personal history of AA seems to be a facilitating factor for the onset of new lesions as reported by Bartels 3 and Posten. 4 Suspension of medication intake seems to be fundamental for hair regrowth.…”
Section: Discussionmentioning
confidence: 64%
“…Personal history of AA seems to be a facilitating factor for the onset of new lesions as reported by Bartels 3 and Posten. 4 Suspension of medication intake seems to be fundamental for hair regrowth.…”
Section: Discussionmentioning
confidence: 64%
“…In fact, a study performed in a private practice could not find a single AA universalis in 135 patients [17]. Although a random coincidence of AA with TNF-α inhibitors may not completely be ruled out in our adult patient, the report of a previous case of AA universalis with adalimumab therapy as well as the possible pathophysiological role of TNF-α in inducing other auto-immune diseases argue against a merely coincidental finding [2, 9]. …”
Section: Discussionmentioning
confidence: 74%
“…The putative role of TNF-α in the pathogenesis of AA has led to attempts to treat AA with TNF-α antagonists like etanercept.However, previous case reports have failed to show efficacy of anti-TNF-α agents in treating AA [6, 7]. Furthermore, even recurrence of AA has been reported with infliximab as well as with adalimumab in a patient with a known history of AA [8, 9]. …”
Section: Discussionmentioning
confidence: 99%
“…In patients treated with adalimumab for rheumatoid arthritis or psoriasis several cutaneous adverse reactions other than new onset psoriasis may occur, including subacute cutaneous lupus erythematosus, vitiligo, urticaria, eczema, dermatitis herpetiformis, perivascular neutrophilic dermatitis, tinea, alopecia areata, and pityriasis rosea 74,75,77,103106. Most of these reactions were mild and did not require discontinuation of treatment.…”
Section: Resultsmentioning
confidence: 99%